HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

rabeprazole (Aciphex)

Subscribe to New Research on rabeprazole

proton pump antagonist; structure given in first source; rabeprazole is the USAN name; inhibits urease

Also Known As:

Aciphex; 1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, sodium salt; 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole; E 3810; E3810; LY-307640; LY307640; Pariet; dexrabeprazole; rabeprazole sodium

Networked: 382 relevant articles (104 outcomes, 118 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Sloan, Sheldon: 10 articles (04/2014 - 06/2002)
2.	Fujimoto, Kazuma: 8 articles (05/2015 - 10/2005)
3.	Robinson, M: 8 articles (11/2003 - 05/2001)
4.	Kinoshita, Yoshikazu: 7 articles (05/2015 - 01/2003)
5.	Hongo, Michio: 7 articles (05/2012 - 12/2010)
6.	Humphries, T J: 7 articles (02/2003 - 04/2000)
7.	Higuchi, Kazuhide: 6 articles (11/2015 - 01/2003)
8.	Kinoshita, Y: 6 articles (10/2014 - 08/2000)
9.	Fujiwara, Yasuhiro: 6 articles (01/2013 - 01/2003)
10.	Kusano, Motoyasu: 6 articles (01/2013 - 03/2011)

Related Diseases

1.	Gastroesophageal Reflux (GERD) 03/01/2002 - "In this large, open-label trial, rabeprazole rapidly and effectively relieved gastro-oesophageal reflux disease symptoms in most patients with erosive oesophagitis. " 04/01/2014 - "Rabeprazole was effective in maintaining endoscopic/histologic healing during a 24-week maintenance period in children with endoscopically proven GERD. " 09/01/2010 - "Rabeprazole was again significantly effective in patients with positive findings for esophageal reflux (p = 0.0025). " 05/01/2008 - "The addition of rabeprazole offered significant improvement in GERD scores in both groups." 07/01/2007 - "Rabeprazole was significantly more effective in erosive GERD than in NERD patients. "
2.	Heartburn (Pyrosis) 05/01/2010 - "The primary efficacy end point, mean percentage of heartburn-free days, was significantly greater with rabeprazole vs. placebo: 82.58% and 62.17% (ITT; P < 0.0001) [per protocol 86.74% rabeprazole vs. 74.93% placebo (P < 0.0254)]. " 06/01/2002 - "After a 2-wk, single-blind placebo run-in phase, patients were randomized to receive 10 mg or 20 mg of rabeprazole or placebo once daily for 4 wk. Rabeprazole rapidly and effectively relieved heartburn, with significant improvements on day 1 of dosing. " 08/01/2000 - "Rabeprazole was also significantly more effective than placebo in preventing relapse of day-and night-time heartburn severity, maintaining overall patient well-being, and reducing antacid use. " 08/01/2000 - "There were also significant differences between the two groups favoring rabeprazole with respect to resolution or improvement of heartburn symptoms and improvement in sense of well-being. " 08/01/2011 - "Administration of 5 mg and 10 mg rabeprazole sufficiently inhibited pathological gastroesophageal acid reflux and relieved heartburn episodes in NERD patients who did not respond to an antacid. "
3.	Infection 11/01/2003 - "pylori infection were recruited for this controlled, randomized, open and parallel-group trial comparing the efficacy of two durations of the same rabeprazole-based triple therapy. " 12/01/2003 - "Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype." 09/01/2001 - "Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism." 03/21/2005 - "Our study showed the eradication rates against H pylori infection 3 and 12 mo after triple therapy were not different between the 3-d and 7-d rabeprazole-based groups. " 11/01/2003 - "The aim of this study was to assess whether there is the possibility of shortening a rabeprazole-based triple therapy from 7 to 4 days without compromising its efficacy in the eradication of Helicobacter pylori infection. "
4.	Peptic Ulcer (Peptic Ulcers) 05/01/2015 - "The aim of this study is to assess the long-term efficacy and safety of rabeprazole for preventing peptic ulcer recurrence on LDA therapy. " 10/01/2014 - "To conduct a randomised, double-blind, triple-dummy, active-controlled, multicentre trial, named the PLANETARIUM study, to assess the efficacy, dose-response relationship and safety of rabeprazole for peptic ulcer recurrence in Japanese patients on long-term LDA therapy. " 04/01/2005 - "To study the efficacy and safety of rabeprazole in peptic ulcer patients alone or combined with anti-Helicobacter pylori (Hp) agents. " 05/01/2015 - "Recurrent peptic ulcers were not observed in the newly-initiated rabeprazole 10- and 5-mg groups. " 05/01/2015 - "The full analysis set consisted of 151 and 150 subjects in the long-term rabeprazole 10- and 5-mg groups, respectively, and the cumulative recurrence rates of peptic ulcers were 2.2 and 3.7%, respectively. "
5.	Duodenal Ulcer (Curling's Ulcer) 01/01/2004 - "[Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)]." 09/01/2002 - "Rabeprazole (10 mg/day) has excellent therapeutic effect on the symptoms of duodenal ulcer patients. " 04/01/2002 - "[Regeneration of the gastric epitheliocytes during treatment of duodenal ulcer with pariet]." 01/01/2002 - "In the article the results of the eradication therapy by Pariet in the patients suffering from the duodenal ulcer disease, associated with Helicobacter pylori (HP), are estimated. " 04/01/2000 - "Rabeprazole is an effective and well-tolerated alternative treatment for patients with active duodenal ulcer disease."

Related Drugs and Biologics

1.	Omeprazole (Esomeprazole)
2.	Proton Pumps (Proton Pump)
3.	Ranitidine (Zantac)
4.	Amoxicillin (Wymox)
5.	Famotidine (Pepcid)
6.	Ofloxacin (Levofloxacin)
7.	lansoprazole (Prevacid)
8.	Proton Pump Inhibitors
9.	Clarithromycin (Biaxin)
10.	rabeprazole (Aciphex)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Cholecystectomy
3.	Complementary Therapies (Alternative Medicine)
4.	Gastrectomy
5.	Esophagectomy